Biogen Inc. (BIIB)
Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock
Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs.
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown
Jefferies downgraded Biogen Inc BIIB, citing the company's tough setup.
Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript
Biogen Inc. (NASDAQ:BIIB ) 7th Annual Evercore ISI HealthCONx Healthcare Conference Call December 3, 2024 9:10 AM ET Company Participants Alisha Alaimo - President and Head of North America Michael McDonnell - Chief Financial Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Okay, thank you guys for joining us. Pleasure to have Biogen Management.
Biogen expects steady growth for Alzheimer's drug Leqembi in near term
Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company executive said at a healthcare conference on Tuesday.
Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
On Tuesday, UCB SA UCBJY UCBJF and Biogen Inc. BIIB presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus erythematosus.
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Needham downgraded Biogen Inc BIIB, citing limited catalysts for the company over the next year.
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease.
Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug
Biogen's stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug.
Biogen initiated with a Neutral at Citi
Citi analyst Geoff Meacham initiated coverage of Biogen with a Neutral rating and $190 price target. The company's strategy to offset core franchise erosion has been to develop assets with significant unmet need in very difficult indications, the analyst tells investors in a research note. The firm says Biogen's pipeline still looks to have higher clinical risk overall versus the company's big biotech peers, "but this also conveys significant option value."
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BIIB vs. MYGN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Biogen Inc. (BIIB) and Myriad Genetics (MYGN). But which of these two stocks offers value investors a better bang for their buck right now?
Are Investors Undervaluing Biogen (BIIB) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
